CytoMed Therapeutics (GDTC) Competitors $2.10 -0.02 (-0.94%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics CytoMed Therapeutics (NASDAQ:GDTC) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Is GDTC or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets CytoMed TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer GDTC or ATNFW? In the previous week, CytoMed Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for CytoMed Therapeutics and 0 mentions for 180 Life Sciences. CytoMed Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment CytoMed Therapeutics Neutral 180 Life Sciences Neutral Which has stronger earnings & valuation, GDTC or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytoMed Therapeutics$50KN/A-$1.84MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Do institutionals and insiders have more ownership in GDTC or ATNFW? 0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer GDTC or ATNFW? CytoMed Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 138.10%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCytoMed Therapeutics beats 180 Life Sciences on 6 of the 6 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E RatioN/A21.5627.4020.04Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book3.447.518.085.67Net Income-$1.84M-$55.05M$3.16B$248.47M7 Day Performance-7.69%3.16%2.12%2.90%1 Month Performance-2.78%5.92%4.43%5.75%1 Year Performance2.94%5.82%35.62%21.36% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics1.8318 of 5 stars$2.10-0.9%$5.00+138.1%+3.7%$0.00$50K0.00N/ANews CoverageGap UpATNFW180 Life SciencesN/A$0.01-1.2%N/A-14.6%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-77.2%$0.00N/A0.002AIMDWAinosN/A$0.13-21.0%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.73+1.8%N/A-42.3%$0.00$585.60M0.004ARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+6.5%N/A-74.1%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.09-1.1%N/AN/A$0.00$38.00M0.0070Gap DownBTMDWbioteN/A$0.02-10.2%N/A-97.9%$0.00$199.38M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.07+13.4%N/A-68.7%$0.00N/A0.008Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GDTC Stock Alerts